Trials / Completed
CompletedNCT01176851
Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers
Pharmacokinetic, Randomized, Open-label, Single-dose, 3-way Cross-over Study of Intravenous and Inhaled Glycopyrrolate With or Without Charcoal Block Ingestion in Healthy Volunteers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the pharmacokinetics, the absolute bioavailability and the lung bioavailability of inhaled Glyco pMDI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glycopyrrolate | Single administration of Glyco pMDI 100 µg |
| DRUG | Glycopyrrolate | Single administration of Glyco pMDI 100 µg after charcoal ingestion |
| DRUG | Glycopyrrolate | Single intravenous injection of glycopyrrolate 100 µg |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2010-08-06
- Last updated
- 2021-10-29
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01176851. Inclusion in this directory is not an endorsement.